As of December 3, 2021, Johnson & Johnson (JNJ) is paying out $4.24 per share in dividends. Johnson & Johnson’s current dividend yield, as of December 03, 2021, is 2.66 percent..
How safe is JNJ dividend?
If you’re looking for Dividend Safety, go no farther than Johnson & Johnson (NYSE: JNJ). Because they’re listed among the elite group of Dividend Kings, the company has paid a rising dividend for more than 50 CONSECUTIVE years.
What is an ex dividend date for a stock?
To decide if you’re entitled to a dividend, you’ll need to look at two dates. Record date or “date of record” and ex-dividend date or “ex-date” are the two terms most commonly used.
On the record date, you must be listed as a shareholder in order to collect the dividend from a publicly traded firm. On this date, companies send their financial reports and other information to shareholders and other interested parties.
Stock market laws dictate that the ex-dividend date is set once the record date has been established by the company. Prior to the record date for dividends, the ex-dividend date is typically one working day earlier. If you buy a stock on or after its ex-dividend date, you will not receive the following dividend. Sellers instead receive the payout. You get the dividend if you buy before the ex-dividend date.
On September 8, 2017, the board of directors of Company XYZ declared a dividend for shareholders to be paid on October 3, 2017. Shareholders of record as of September 18, 2017 are eligible for the dividend, XYZ said in a statement. One business day prior to the record date, the stock would go ex-dividend.
Monday is the record date in this example. Prior to record date or opening of market, ex-dividend is fixed one business day prior to record date or opening of market. Those who purchased the stock after Friday will not be entitled to a dividend. Additionally, individuals who buy before Friday’s ex-dividend date will be entitled to the payout.
On the ex-dividend day, a stock’s price may drop by the dividend amount.
The ex-dividend date is determined differently if the dividend is 25% or more of the stock’s value.
If the dividend is paid on a Friday, the ex-dividend date will be delayed until the next business day.
For a company that pays a dividend equal to 25% or more of its value, the ex-dividend date is October 4, 2017.
In some cases, a dividend is paid in the form of stock rather than cash, rather than cash. Additional shares in the company or in a subsidiary that is being spun off are possible stock dividends. Unlike cash dividends, stock dividends may have various methods. The ex-dividend date is established on the first business day following the payment of the stock dividend (and is also after the record date).
Before the ex-dividend date, if you sell your stock, you forfeit your claim to the dividend. Because the seller will obtain an IOU or “due bill” from his or her broker for the additional shares, you have an obligation to provide the additional shares to the buyer of your shares. Remember that the first business day after the record date is not the first business day after the stock dividend is paid, but rather the first business day following the dividend payment.
Please seek the advice of your financial advisor in the event that you have queries concerning specific dividends.
Is JNJ a dividend aristocrat?
Atmos Energy expects to see a 6% to 8% annual increase in its adjusted earnings-per-share as a result of new customers and rate base expansion.
Atmos Energy has a long history of dividend growth thanks to its strong competitive advantages. As a regulated utility with a blended allowable return on equity of 9.8 percent, Atmos Energy may expect to receive a consistent level of earnings. This ensures that the company will continue to generate revenue. For the past 18 years, Atmos Energy’s earnings-per-share have increased.
Atmos Energy’s business model is very recession-resistant because it is a utility. Even in the depths of a severe recession, people will always require utility services, ensuring that the company’s dividends will continue to grow. There are 72,000 miles of distribution and transmission mains, 5,700 miles of interstate pipelines, and five storage facilities with a total capacity of 46 billion cubic feet of natural gas working capacity in the company’s network of assets.
If you look at Atmos Energy’s dividend safety and long-term growth, you will see that it appears to have a high level of stability. 37 years in a row, the dividend has been increased by the corporation.
A long-term dividend payout target of 50% is set by the corporation. To ensure that the company has enough money to engage in growth initiatives while still having enough money to pay out dividends, this long-term payout ratio is ideal.
Atmos Energy’s fiscal 2021 outlook predicts EPS of $5.00 at the company’s midpoint, with a current annualized dividend payout of $2.50 per share.
In comparison to our fair value assessment, the stock currently has a price-to-earnings ratio somewhat above 20. It’s not uncommon for a high-quality blue-chip firm to have a premium multiple, even if today’s stock prices are a bit expensive. As a result, we don’t expect a major shift in the value multiple in the near future.
Over the next five years, we predict the company’s EPS to expand at a rate of 6%. Over the course of the following five years, investors may expect to see a total return of almost 8% each year.
Dividend Aristocrat #3: Johnson & Johnson (JNJ)
It is the most valuable healthcare corporation in the United States, with a market value in excess of $400 billion. Since its inception, it has grown steadily and expanded its business approach, resulting in a colossal size. J&J is a major player in the medical device, pharmaceutical, and consumer healthcare industries, all of which it dominates.
In 2020, the aggregate revenue of these enterprises will exceed $82 billion. J&J’s sales increased last year despite the recession caused by the coronavirus outbreak.
As the economy heals, the company has continued to grow. J&J’s first-quarter revenue increased by 8% to $22.3 billion in 2021. Shareholder value climbed by 13 percent from the same period last year.
Last quarter, J&J’s pharmaceutical division had a 10% increase in revenue due to a 19% increase in cancer sales. A few of its best-known individual drugs include Darzalex (multiple myelodysplastic syndrome) and Imbruvica (leukemia). While Stelara continues to gain market share, J&J’s Immunology revenue climbed by 8%.
There was an 11% increase in medical device sales, which was driven by a 30% increase in International Solutions’ revenue.
Since the 1880s, J&J has been in business. Investing so heavily in healthcare R&D has helped this company rise to prominence. In order to accomplish this, J&J spent more than $12 billion on R&D in 2013. This investment aids the company’s ability to come up with innovative cures that will help it grow in the future.
There are now 28 platforms or individual items that generate more than $1 billion in annual revenue for J&J as a result of the company’s investment. J&J has established a huge business thanks to a wide range of industry-leading products, as well as the diversification benefits of not being unduly vulnerable to any one product line..
This year, the company hopes to see continued growth in 2021. J&J has boosted its full-year forecast and now expects adjusted earnings per share of $9.42 to $9.57, up from $9.40 to $9.60. J&J’s adjusted EPS is expected to climb by 18 percent year-over-year at the midpoint of this estimate.
Six percent annual growth in adjusted EPS is expected over the next five years for the company. As a result, shares don’t appear to be overvalued at this time. J&J stock has a price-to-earnings ratio of 17.9 based on its 2021 forecast.
J&J stock is not excessively expensive, even though we estimate its fair value to be 17 times earnings per share. Investors are more than justified in paying a modest premium for a blue-chip company like J&J, which rarely trades for discounted valuation multiples.
Even if the company’s P/E multiple doesn’t rise in the future, its EPS growth and dividend yield (now at 2.5 percent) should still generate high-single digit total returns.. For the past 59 years, Johnson & Johnson has grown its dividend. Dividend Aristocrat and Dividend King because of its long-term dividend growth record.
Dividend Aristocrat #2: AbbVie Inc. (ABBV)
Founded in 2013, AbbVie is a pharmaceutical company set off from Abbott Laboratories (ABT). From 2013 through 2020, AbbVie claims it delivered yearly sales growth of 13.5 percent and adjusted earnings per share growth of 18.8 percent.
To succeed in the future, AbbVie must overcome a major obstacle. Several international regions, notably Europe, are now facing biosimilar competition for Humira, and the U.S. will lose patent exclusivity in 2023.
To replenish its pipeline, AbbVie has spent extensively in its own research and development infrastructure. In 2020, R&D expenses at AbbVie are expected to reach $6.5 billion. The immunology, hematology, and neurology therapeutic areas, in particular, offer numerous growth potential for it to take the position of Humira. There are several new drugs AbbVie hopes will become blockbusters as a result of these investments. In the most recent quarter, Skyrizi sales surged by 89 percent, while Rinvoq revenue increased by more than double year-over-year.
Next, AbbVie’s $63 billion acquisition of Allergan provides it with access to the fast-growing global aesthetics market. Botox is Allergan’s most popular product. Profits from AbbVie’s beauty portfolio climbed 35% year-over-year in the first quarter to reach $1.1 billion.
AbbVie made $13 billion in revenue in the first quarter of 2021, up 51% from the same period last year. Over the past year, earnings per share increased by 22%. AbbVie also boosted its full-year forecast after reporting its first-quarter results. An adjusted EPS range of $12.37-$12.57 is now expected for AbbVie for the year of 2021. This year, AbbVie’s adjusted earnings per share (EPS) is predicted to rise by 18 percent, making it another year of robust growth for the pharmaceutical company.
Over the next five years, we predict the company’s EPS will expand by 3%. Due to the increased R&D spending required to keep developing its pipeline, we believe this projection is highly conservative.
Next, we believe the stock is undervalued. AbbVie stock has a P/E ratio of only 9.3 based on the company’s predicted adjusted EPS for 2021. AbbVie is a highly lucrative and expanding corporation, yet its price multiple is quite low.
We believe that AbbVie’s low valuation multiple is a result of investor pessimism regarding the company’s future as it relates to Humira.. Even so, we consider a price-to-earnings ratio of at least 10 to be a sign of fair value. For investors, a rise in valuation multiples could provide a little lift in returns in the future.
Last but not least, AbbVie stock currently pays a dividend of 4.5%, which is much better than what you’ll get from the S&P 500 Index, which currently pays just 1.4%. We predict total returns of more than 9% per year based on the combination of projected EPS growth, a growing valuation multiple, and dividend payouts.
dividend growth stock, and AbbVie is just that. Since Abbott’s spin-off, it has reported strong dividend increases. AbbVie’s quarterly dividend climbed by 225 percent from 2013 to 2020, according to the firm.
Dividend Aristocrat #1: Becton, Dickinson & Company (BDX)
In the medical supply industry, Becton, Dickinson & Co. is a global leader. Revenues from outside the United States account for 45 percent of the company’s total annual revenue.
Medical Devices, Life Sciences, and Intervention are the three segments that BDX now operates in. Needles for medication delivery systems and surgical blades are among the Medical Devices segment’s products.
The coronavirus pandemic has had no effect on BDX’s performance over the past year. BDX recorded a 15% increase in revenue in the most recent quarter, compared to the same period last year.
The Medication Delivery Solutions business continues to be the driving force behind the Medical segment’s sales growth of 4.7 percent. A resurgence in lab activity has resulted in a 38 percent rise in Life Science revenue. At slightly over $1 billion, Interventional revenue remained virtually unchanged.
Additional financial figures were released along with fiscal 2021 forecasts. BDX’s management estimates its adjusted EPS to be in the $12.75 to $12.85 range. On a currency-neutral basis, revenue is expected to climb between 10 and 12 percent in fiscal 2021. The aging population and the rise of emerging countries are likely to continue to drive the company’s growth in 2021.
In the first place, an aging population plagues many wealthy countries like the United States. Demand for healthcare products and services is expected to continue to climb as the Baby Boomer population grows older. BDX’s domestic expansion will be bolstered by this inherent advantage.
Another important driver of BDX’s growth is the company’s international presence, notably in the rapidly expanding emerging markets. According to BDX’s last quarterly earnings report, the majority of the company’s overseas revenue came from countries that are still developing. The company’s foreign revenue expanded by 26 percent, with 10 percent growth in developed countries and 24 percent growth in emerging markets, including a 62 percent increase in China.
BDX stock presently has a price-to-earnings ratio of 19.1 based on a projected adjusted EPS of $12.80 for fiscal 2021, which is the midpoint of management projection. The stock’s 10-year average P/E multiple is 18.6, thus our objective price-to-earnings ratio is 18.6. A small overvaluation of the stock will have little effect on future shareholder returns.
A P/E multiple of 18.6 for the next five years would only diminish yearly shareholder returns by 0.5 percent during that time. In addition, future earnings-per-share growth and dividends would improve shareholder returns.
Over the next five years, we believe BDX’s competitive advantages and growth potential from the numerous catalysts outlined above to result in a 10% annual EPS growth rate. Finally, the company’s shares currently yield 1.4 percent in dividends.
This means that BDX’s five-year total returns are expected to be approximately 10.9 percent. This is a high projected rate of return, especially for a well-known dividend company like Blue Chips.. We consider BDX to be our top-ranked dividend aristocrat at this time.
What is Walmart’s dividend yield?
Since 1989, Walmart (WMT) has paid out dividends to shareholders. As of December 3, 2021, Walmart (WMT) is paying out a dividend of $2.20 per share in the last twelve months. As of December 3, 2021, Walmart’s dividend yield is 1.60 percent.
What is Procter & Gamble’s dividend?
As a whole, Procter and Gamble has a lengthy history of dividends. For decades, the corporation has weathered a variety of difficulties and has maintained its dividend. The coronavirus pandemic is the most recent in a long list of issues. The things it sells are a big part of why it’s been so successful for so long. Paper towels and laundry detergent are household necessities regardless of the economic cycle.
What is Coca Cola dividend?
For than a century, Coca-Cola has been providing people with a refreshing beverage. With a focus on restaurants, cinemas, and theme parks, the company makes and sells its drinks around the world. It had a harmful effect during the coronavirus pandemic, but now that the economy has recovered, the policy is actually beneficial.”
In addition to the dividend of $0.42 per share, Coca-quarterly Cola’s dividend yield is 3.07 percent. There’s been an increase in a company’s dividend payout ratio in recent years, which is the percentage of earnings that are distributed to shareholders as dividends. Because eventually the company runs out of cash, a dividend payout ratio of more than 100% is unsustainable.
How often are dividends paid?
How often are dividends given out? Although some corporations in the United States pay dividends monthly or semiannually, the majority pay quarterly in the United States. Each dividend must be approved by the company’s board of directors. As soon as this information is made public, investors will know exactly when and how much of a dividend they will receive.
Do Tesla pay dividends?
On our common stock, Tesla has never paid a dividend. Due to our long-term investment strategy, we do not anticipate paying out any cash dividends in the near future.
